Art. 38 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 16×
1.

Without prejudice to Article 71 of Directive 2001/82/EC, a marketing authorisation which has been granted in accordance with this Regulation shall be valid throughout the Union. It shall confer the same rights and obligations in each of the Member States as a marketing authorisation granted by that Member State in accordance with Article 5 of Directive 2001/82/EC.

Authorised veterinary medicinal products shall be entered in the Union Register of Medicinal Products and shall be given a number which shall appear on the packaging.

2.

Notification of marketing authorisation shall be published in the Official Journal of the European Union, quoting in particular the date of authorisation and the number in the Union Register, any International Non-proprietary Name (INN) of the active substance of the medicinal product, its pharmaceutical form, and any Anatomical Therapeutic Chemical Veterinary Code (ATC Vet Code).

3.

The Agency shall immediately publish the assessment report on the veterinary medicinal product drawn up by the Committee for Medicinal Products for Veterinary Use and the reasons for its opinion in favour of granting authorisation, after deletion of any information of a commercially confidential nature.

The European Public Assessment Report (EPAR) shall include a summary written in a manner that is understandable to the public. The summary shall contain in particular a section relating to the conditions of use of the medicinal product.

4.

After a marketing authorisation has been granted, the holder of the authorisation shall inform the Agency of the dates of actual placing on the market of the veterinary medicinal product in Member States, taking into account the various presentations authorised.

The holder shall also notify the Agency if the product ceases to be placed on the market, either temporarily or permanently. Such notification shall, other than in exceptional circumstances, be made no less than 2 months before the interruption in the placing of the product on the market.

Upon request by the Agency, particularly in the context of pharmacovigilance, the marketing authorisation holder shall provide the Agency with all data relating to the volume of sales of the medicinal product at Union level, broken down by Member State, and any data in the holder's possession relating to the volume of prescriptions.

The 10 that are cited most themselves, of 16.

  • Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law

    … предписан продукт, както е предвидено в член 13, параграф 4 и член 38, параграф 4 от Регламент (ЕО) № 726/2004; 11. задължението за прилагане …

  • Ordonnance du président du Tribunal du 20 juillet 2016. MSD Animal Health Innovation GmbH et Intervet international BV contre Agence européeDecision

    Under Article 38(3) of Regulation No 726/2004, the EMA is to publish the European Public Assessment Report (‘EPAR’) on the veterinary medicinal product drawn up by the CVMP, namely a summary of the product’s characteristics that is …

    20 Jul 2016 · 62015TO0729

  • Judgment of the General Court (Second Chamber, Extended Composition) of 5 February 2018. Pari Pharma GmbH v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the EPAR, a summary of the characteristics of the medicinal products …

    5 Feb 2018 · 62015TJ0235

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the European Public Assessment Report (‘the EPAR’), a summary of the …

    5 Feb 2018 · 62015TJ0718

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v MSD Animal Health Innovation GmbH and Intervet iDecision

    Under Article 38(3) of Regulation No 726/2004, the EMA, after examining the MA application, is to publish the European Public Assessment Report on the medicinal product for veterinary use (‘the EPAR’), containing a summary of the …

    1 Mar 2017 · 62016CO0512

  • Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EC) No 1234…1Law

    … продукти на Общността, предвиден в член 13, параграф 1 и член 38, параграф 1 от Регламент (ЕО) № 726/2004, се актуализира съответно.“ 14) Член …

  • Judgment of the General Court (Second Chamber) of 5 February 2018. MSD Animal Health Innovation GmbH and Intervet international BV v EuropeaDecision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the European Public Assessment Report (‘the EPAR’), a summary of the …

    5 Feb 2018 · 62015TJ0729

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … предписан продукт, както е предвидено в член 13, параграф 4 и член 38, параграф 4 от Регламент (ЕО) № 726/2004; 11. задължението за прилагане …

  • Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law

    … data relating to the volume of sales and the volume of prescriptions of the product, as provided in Article 13(4) and Article 38(4) of Regulation (EC) No 726/2004; the obligation to operate a comprehensive pharmacovigilance system for the …

  • Regulation (EU) 2019/5Lawamends